These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12435777)

  • 21. Monitoring of lipodystrophic and metabolic abnormalities in HIV-1 infected children on antiretroviral therapy.
    Spoulou V; Kanaka-Gantenbein C; Bathrellou I; Mora S; Mostrou G; Sidossis L; Chrousos G; Theodoridou M
    Hormones (Athens); 2011; 10(2):149-55. PubMed ID: 21724540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Lipodystrophy and echographic hepatic steatosis in HIV-positive patients under highly active antiretroviral therapy (HAART) in Yaounde (Cameroon)].
    Ongolo-Zogo P; Nkodo Mbia N; Mvogo Minkala TL; Biwole Sida M; Kouanfack C; Nko Amvene S
    Bull Soc Pathol Exot; 2012 Dec; 105(5):353-60. PubMed ID: 22886433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors.
    Introcaso CE; Hines JM; Kovarik CL
    J Am Acad Dermatol; 2010 Oct; 63(4):549-61; quiz 561-2. PubMed ID: 20846563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence and risk factors of severe hypertriglyceridaemia in the era of highly active antiretroviral therapy: the Aquitaine Cohort, France, 1996-99.
    Thiébaut R; Dequae-Merchadou L; Ekouevi DK; Mercié P; Malvy D; Neau D; Dabis F;
    HIV Med; 2001 Apr; 2(2):84-8. PubMed ID: 11737383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipoatrophy and lipohypertrophy are independently associated with hypertension.
    Crane HM; Grunfeld C; Harrington RD; Kitahata MM
    HIV Med; 2009 Sep; 10(8):496-503. PubMed ID: 19486188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence of lipodystrophy and metabolic disorders in patients starting non-nucleoside reverse transcriptase inhibitors in Benin.
    Zannou DM; Denoeud L; Lacombe K; Amoussou-Guenou D; Bashi J; Akakpo J; Gougounon A; Akondé A; Adé G; Houngbé F; Girard PM
    Antivir Ther; 2009; 14(3):371-80. PubMed ID: 19474471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children.
    Sánchez Torres AM; Munoz Muniz R; Madero R; Borque C; García-Miguel MJ; De José Gómez MI
    Eur J Pediatr; 2005 May; 164(5):271-6. PubMed ID: 15650834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipodystrophy and metabolic complications of highly active antiretroviral therapy.
    Parakh A; Dubey AP; Kumar A; Maheshwari A
    Indian J Pediatr; 2009 Oct; 76(10):1017-21. PubMed ID: 19907933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV-associated facial lipoatrophy.
    James J; Carruthers A; Carruthers J
    Dermatol Surg; 2002 Nov; 28(11):979-86. PubMed ID: 12460289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of lipodystrophy in HIV-infected children in Tanzania on highly active antiretroviral therapy.
    Kinabo GD; Sprengers M; Msuya LJ; Shayo AM; van Asten H; Dolmans WM; van der Ven AJ; Warris A
    Pediatr Infect Dis J; 2013 Jan; 32(1):39-44. PubMed ID: 23038217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada.
    Andany N; Raboud JM; Walmsley S; Diong C; Rourke SB; Rueda S; Rachlis A; Wobeser W; Macarthur RD; Binder L; Rosenes R; Loutfy MR
    HIV Clin Trials; 2011; 12(2):89-103. PubMed ID: 21498152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipodystrophy in HIV-infected pediatric patients receiving protease inhibitors.
    Temple ME; Koranyi KI; Nahata MC
    Ann Pharmacother; 2003 Sep; 37(9):1214-8. PubMed ID: 12921501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens.
    Taylor P; Worrell C; Steinberg SM; Hazra R; Jankelevich S; Wood LV; Zwerski S; Yarchoan R; Zeichner S
    Pediatrics; 2004 Aug; 114(2):e235-42. PubMed ID: 15286262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of lipodystrophy and metabolic syndrome among HIV positive individuals on Highly Active Anti-Retroviral treatment in Jimma, South West Ethiopia.
    Berhane T; Yami A; Alemseged F; Yemane T; Hamza L; Kassim M; Deribe K
    Pan Afr Med J; 2012; 13():43. PubMed ID: 23330034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics and factors associated with the clinical forms of lipoatrophy during highly active antiretroviral therapy in Ouagadougou, Burkina Faso.
    Guira O; Tiéno H; Yaméogo B; Diendéré AE; Korsaga N; Sagna Y; Zoungrana L; Diallo I; Traoré R; Drabo JY
    J Int Assoc Provid AIDS Care; 2014; 13(2):184-7. PubMed ID: 24114724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and biochemical evaluation of HIV-related lipodystrophy in an ambulatory population from the Hospital Universitário Cassiano Antonio de Morais, Vitória, ES, Brazil.
    Monnerat BZ; Cerutti Junior C; Caniçali SC; Motta TR
    Braz J Infect Dis; 2008 Aug; 12(4):364-8. PubMed ID: 19030742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipoatrophy among HIV-infected patients is associated with higher levels of depression than lipohypertrophy.
    Crane HM; Grunfeld C; Harrington RD; Uldall KK; Ciechanowski PS; Kitahata MM
    HIV Med; 2008 Oct; 9(9):780-6. PubMed ID: 18754804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lower levels of IL-4 and IL-10 influence lipodystrophy in HIV/AIDS patients under antiretroviral therapy.
    Dragović G; Dimitrijević B; Khawla AM; Soldatović I; Andjić M; Jevtović D; Nair D
    Exp Mol Pathol; 2017 Apr; 102(2):210-214. PubMed ID: 28189545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors for lipodystrophy in the CISAI cohort.
    Bonfanti P; Gulisano C; Ricci E; Timillero L; Valsecchi L; Carradori S; Pusterla L; Fortuna P; Miccolis S; Magnani C; Gabbuti A; Parazzini F; Martinelli C; Faggion I; Landonio S; Quirino T; Vigevani G;
    Biomed Pharmacother; 2003 Nov; 57(9):422-7. PubMed ID: 14652168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.